Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling.
Journal: NPJ systems biology and applications
Published: July 31, 2019
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Journal: The Lancet. Haematology
Published: November 15, 2018
Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.
Journal: The AAPS journal
Published: November 29, 2016
An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
Journal: Blood
Published: August 24, 2016
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 24, 2016
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Journal: Science translational medicine
Published: May 15, 2015
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Journal: The Lancet. Oncology
Published: May 01, 2015
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Journal: Molecular cancer therapeutics
Published: April 20, 2013
Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.
Journal: Future oncology (London, England)
Published: March 09, 2013
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 06, 2013
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Journal: Clinical pharmacology in drug development
Published: February 25, 2012
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.
Journal: Cancer chemotherapy and pharmacology
Published: February 07, 2012
Last Updated: 09/26/2026